Long-term follow-up of multiple myeloma after autologous hematopoietic stem cell transplantation: a single center results
10.3760/cma.j.issn.0253-2727.2017.06.007
- VernacularTitle: 多发性骨髓瘤患者自体造血干细胞移植后长期随访的单中心结果
- Author:
Weiwei SUI
1
;
Dehui ZOU
;
Gang AN
;
Shuhua YI
;
Shuhui DENG
;
Wenyang HUANG
;
Tingyu WANG
;
Jian LI
;
Hong LIU
;
Mingwei FU
;
Rui LYU
;
Wei LIU
;
Yan XU
;
Zengjun LI
;
Yaozhong ZHAO
;
Lugui QIU
Author Information
1. State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Hematopoietic stem cell transplantation;
Prognosis
- From:
Chinese Journal of Hematology
2017;38(6):499-504
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and long-term outcome of a combined protocol for multiple myeloma (MM) , including induction therapy, autologous hematopoietic stem cell transplantation (ASCT) and consolidation and maintenance therapy.
Methods:Clinical records of 144 patients with MM from January 1, 2005 to February 1, 2016 were retrospectively analyzed.
Results:The overall response rate (ORR) after ASCT was 100.0%, in which the complete remission (CR) was 64.1% and the best treatment response rate of superior to PR was 89.4%. During a median follow-up of 47 months, patients with an overall survival (OS) and progression free survival (PFS) was 120.9 and 56.9 months respectively. 5y-OS (73.7±4.7) %, 7y-OS (60.5±6.3) %; 3y-PFS (69.2±4.2) %, 5y-PFS (47.8±5.3) %. The median OS and PFS between the first line transplantation group and salvage transplantation group were 120.9 months vs 50.1 months and 60.2 months vs 16.7 months (all P=0.000). In 127 patients with R-ISS staging, the median survival of Ⅰ, Ⅱ, Ⅲ stage was 120.9 months (n=43) , 88.4 months (n=64) , 35.6 months (n=20) , respectively (P=0.000). For subgroup analysis of survival in early and late ASCT, the median OS of patients with R-ISS stage Ⅲ (35.6 months vs 15.8 months, P=0.031) and the median PFS of two groups (phase Ⅰ: 72.1 months vs 18.9 months, P=0.000; Ⅱ: 53.4 months vs 16.7 months, P=0.012; Ⅲ: 28.5 months vs 5.9 months, P=0.001) were different. Multivariate analysis showed that only R-ISS and the degree of remission before transplantation had impact on OS (HR=8.486, 95% CI 2.549-28.255, P=0.003) and PFS (HR=2.412, 95% CI 1.364-4.266, P=0.002) , respectively.
Conclusion:The combined protocol containing ASCT is effective for MM patients, improving remission rate and remission depth, prolonging PFS and OS. First line transplantation could significantly prolong the OS and PFS as compared with salvage transplantation. R-ISS and pre-transplantation remission depth are prognostic factors for survival.
